ArticlePloS one2009
Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission.AIDS (London, England) · 2012Pooled it
- The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.The Journal of infectious diseases · 2012Trial
- Comparison of two simulators for individual based models in HIV epidemiology in a population with HSV 2 in Yaoundé (Cameroon).Scientific reports · 2021Article
- The role of CD38 in HIV infection.AIDS research and therapy · 2021Review
- AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort: cohort profile.BMJ open · 2018Observational
- Relational concurrency, stages of infection, and the evolution of HIV set point viral load.Virus evolution · 2018Article
- Modelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxis.Evolutionary applications · 2017Article
- The impact of antiretroviral therapy on population-level virulence evolution of HIV-1.Journal of the Royal Society, Interface · 2015Article
- CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time.AIDS (London, England) · 2015Article
- Disease progression of HIV-1 infection in symptomatic and asymptomatic seroconverters in Osaka, Japan: a retrospective observational study.AIDS research and therapy · 2015Article
- Associations of host genetic variants on CD4⁺ lymphocyte count and plasma HIV-1 RNA in antiretroviral naïve children.The Pediatric infectious disease journal · 2014Article
- An HIV epidemic model based on viral load dynamics: value in assessing empirical trends in HIV virulence and community viral load.PLoS computational biology · 2014Article
- Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic.PLoS genetics · 2014Article
- Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective.Science (New York, N.Y.) · 2014Review
- Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013.Retrovirology · 2013Review
- Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?AIDS (London, England) · 2013Article
- Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in Japan.Journal of virology · 2013Article
- Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection.Journal of virology · 2013Article
- How effectively can HIV phylogenies be used to measure heritability?Evolution, medicine, and public health · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHIV-1 RNA plasma concentration at viral set-point is associated not only with disease outcome but also with the transmission dynamics of HIV-1. We investigated whether plasma HIV-1 RNA concentration and CD4 cell count at viral set-point have changed over time in the HIV epidemic in the Netherlands. METHODOLOGY/PRINCIPAL
findingsWe selected 906 therapy-naïve patients with at least one plasma HIV-1 RNA concentration measured 9 to 27 months after estimated seroconversion. Changes in HIV-1 RNA and CD4 cell count at viral set-point over time were analysed using linear regression models. The ATHENA national observational cohort contributed all patients who seroconverted in or after 1996; the Amsterdam Cohort Studies (ACS) contributed seroconverters before 1996. The mean of the first HIV-1 RNA concentration measured 9-27 months after seroconversion was 4.30 log(10) copies/ml (95% CI 4.17-4.42) for seroconverters from 1984 through 1995 (n = 163); 4.27 (4.16-4.37) for seroconverters 1996-2002 (n = 232), and 4.59 (4.52-4.66) for seroconverters 2003-2007 (n = 511). Compared to patients seroconverting between 2003-2007, the adjusted mean HIV-1 RNA concentration at set-point was 0.28 log(10) copies/ml (95% CI 0.16-0.40; p<0.0001) and 0.26 (0.11-0.41; p = 0.0006) lower for those seroconverting between 1996-2002 and 1984-1995, respectively. Results were robust regardless of type of HIV-1 RNA assay, HIV-1 subtype, and interval between measurement and seroconversion. CD4 cell count at viral set-point declined over calendar time at approximately 5 cells/mm(3)/year.
conclusionThe HIV-1 RNA plasma concentration at viral set-point has increased over the last decade of the HIV epidemic in the Netherlands. This is accompanied by a decreasing CD4 cell count over the period 1984-2007 and may have implications for both the course of the HIV infection and the epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.